Author Archives: admin


Stem Cell Clinic > Articles by: admin

Whats Causing Black Fungus? Here Is What The Doctors Have To Say – The Logical Indian

By Stem Cell Doctors

As of May 24, over 9,000 black fungus cases have been reported in India. In the light of the increasing rise in the number of cases, several states like Delhi, Rajasthan, Gujarat, Odisha, Telangana and Maharashtra have already declared the disease as an epidemic.

Black Fungs or Mucormycosis is caused due to exposure to mucor mould, which is widely found in soil, plants, manure, and rotting fruits and vegetables. Micromycetes are a type of mould that causes this infection. However, it is not a contagious disease, which means that it does not transmit from one person to another.

Headaches, nasal congestion, facial pain, loss of vision or pain in the eyes, swelling in the cheeks and eyes, and black crusts in the nose are all common symptoms of the Black fungus. According to the US Centers for Disease Control and Prevention, Mucormycosis has a 54 percent overall all-cause mortality rate.

1. Weak Immune System

The rare fungal infection primarily affects individuals with a weaker immune system. Since Covid-19 already affects the immune system, they become more prone to Black Fungus. Furthermore, cancer patients who have had an organ transplant or stem cell transplant, neutropenia (low white blood cell count), long-term corticosteroid use, iron overload in the body, skin lesions from surgery, burns or wounds, preterm, and low birth weights are more susceptible to mucormycosis infection.

2. Usage of Excessive Steroids

Experts have mentioned that diabetic Covid-19 patients are at a higher risk of catching black fungus. Since steroids are used in treatment during the second week, if the patient is severe, it makes them prone to the infection. The acidic environment found in diabetic ketoacidosis is ideal for these organisms' fast proliferation. Diabetes is also linked to a weakened immune system, which allows the fungus to evade detection and destroy all tissues.

3. Reusing A Mask

According to medical experts, reusing a mask or remaining in a room with insufficient ventilation has been linked to the development of mucormycosis. "I would reckon is unhygienic practices, like wearing masks over a long time without washing them, or staying in poorly ventilated rooms such as a basement, or less airy rooms. So, I would say, the second factor is also a trigger point for contractor mucormycosis," Dr Suresh Singh Naruka said to Zee News.

4. Antibiotics, Zinc and Steaming

Dr Rajeev Jayadevan, a gastroenterologist, identified three potential causes for Black fungus: antibiotics, zinc, and steaming. Antibiotics, he added, have been proven to exacerbate the fungal infection.

"Fungi thrive in zinc-rich environments, and mammalian cells fight to keep zinc away from fungus to avoid infection," he said, indicating that zinc could be a factor. He explained that excess steam could damage the delicate mucus layer and even produce burns along the mucosa, making it simple for fungus to breach our natural defence. "Burns were responsible for 10-20% of the previous mucormycosis in India," Dr Rajeev told The Print.

5. Cold Oxygen

Cold oxygen is another factor that can contribute to developing Black Fungus. It is extremely harmful to provide cold oxygen directly from the cylinder. "Anti-fungal drug Posaconazole can be given to high-risk individuals to reduce incidents of black fungus," Dr P Sarat Chandra said to Hindustan Times.

Niti Aayog member V.K. Paul, at a briefing on Saturday, said that a link between steroid use for Covid treatment and mucormycosis or black fungus, a disease being widely reported among patients who have recovered from coronavirus, could not be denied.

However, a former president of the Indian Medical Association's Cochin chapter has pointed out that the government must widen its search for the cause of the sudden black fungus outbreak, which has been declared an epidemic by several states.

Also Read: #SaveLakshadweep: Why Are Island Residents Seeking National Attention After New 'Draconian' Bill?

Continued here:
Whats Causing Black Fungus? Here Is What The Doctors Have To Say - The Logical Indian

University of Pittsburgh Won’t Explain its Planned Parenthood Ties | Opinion – Newsweek

By Stem Cell Doctors

I testified at the Pennsylvania House Health Committee's hearing on "Fetal Experimentation" earlier this month.

Pennsylvania has a pro-life reputation, yet the University of Pittsburgh hosts disturbing and barbaric government-sponsored experiments on aborted babies: infant scalping, exporting fetal kidneys and killing live-aborted infants by organ harvesting. Mounting evidence connects Planned Parenthood to it all.

Despite the serious questions about these experiments and Pitt's inextricable relationship with Planned Parenthood, Pitt stonewalled lawmakers with an unprepared, newly hired witness who could not answer basic questions. Perhaps Pitt could not send a qualified witness to defend these programs, because what takes place in them is indefensible.

In one study published last year, Pitt scientists described scalping 5-month-old aborted babies to stitch onto the backs of lab rats. They wrote about how they cut the scalps from the heads and backs of the babies, scraping off the "excess fat" under the baby skin before stitching it onto the rats. They even included photos of the babies' hair growing out of the scalps. Each scalp belonged to a little Pennsylvania baby whose head would grow those same hairs if he or she were not aborted for experiments with lab rats.

Pitt's explanation? "Lab mice, not lab rats," the university's witness told the committee indignantly.

In fact, the published study used both rats and mice to grow the babies' scalps. How was this paid for? With a $430,000 grant from Dr. Anthony Fauci's NIAID office at the NIH. Pitt's witness implied that government NIH grants somehow did not concern taxpayers in Pennsylvania.

Previously, I wrote about another Pitt scientist who developed a nightmarish "protocol" for harvesting the freshest, most pristine livers from 5-month-old aborted babies in order to isolate massive numbers of stem cells for experimental transplants. This technique calls for aborting late-term fetuses alive via labor induction, rushing them to a sterile laboratory, washing them and then cutting them open to harvest the liver. This Pitt scientist received $3 million from the NIH.

At the hearing, Pitt asserted, without evidence, that this experiment was done only in Italy and ended in 2013. But the Pitt scientist responsible published further research in 2019 and described obtaining the same uniquely massive, two-billion-stem-cell yield from "complete" fetal livers harvested in Pittsburghindicating the same technique he outlined was still being used in America.

Starting in 2016, Pitt received $1.4 million in NIH grants to operate a distribution "hub" for aborted fetal kidneys and other organs in NIH's GenitoUrinary Development Molecular Anatomy Project. Pitt's grant application advertises the university's unique access to a large number of high-quality aborted fetuses and that "collections can be significantly ramped up."

Pennsylvania law makes experimentation on a living fetus or failure to provide immediate medical care to a born-alive infant a third-degree felony. Sadly, fetal experimentation, including on babies delivered alive in late-term abortions, has been documented at Pitt for decades.

Astonishingly, at and after the hearing, Pitt doubled down on a demonstrably false talking point: "There is no procurement relationship for tissue with Planned Parenthood."

Pitt's fetal research projects generally obtain fetal tissue through the university's tissue bank from local abortion providers. Two years ago, sources told me Pittsburgh was one of the major hubs of the FBI's investigation into Planned Parenthood's human trafficking of aborted fetuses. Planned Parenthood Western Pennsylvania (PPWP) abortion providers, who were on staff at Pitt, confirmed this information. When I was undercover, they told me they supply the university's tissue bank.

What is Pitt so afraid of admitting?

Since 2005, Pitt has been a major location for Planned Parenthood's Ryan Residency and Family Planning Fellowship abortion training programs. Some of the most notorious Planned Parenthood abortion doctors came up through the program.

Dr. Jennefer Russo, VP of Planned Parenthood Orange and San Bernardino Counties, supplied the aborted fetuses to the criminal company DaVinci Bioscienceswhich admitted to illegally selling the fetal body parts and was shut down by local law enforcement. She did her abortion training fellowship at Pitt. And there are many others.

Today, Dr. Beatrice Chen, PPWP's medical director, also runs the abortion programs at Pitt. Dr. Sharon Achilles, the laboratory director at PPWP and a prominent Pitt faculty member, is on Planned Parenthood Federation of America's National Medical Committee.

Shockingly, Dr. Chen is also vice chair of the university's Institutional Review Board, which reviews and supervises all fetal research projects. This obvious conflict of interest makes the Pitt-and-Planned-Parenthood lead abortionist a supervising participant in every fetal research project, contravening federal requirements that fetal researchers be separated from clinical abortion practice.

Planned Parenthood Western Pennsylvania, meanwhile, is a "contracted care" site for Pitt, receiving access to medical students, medical resources, medical infrastructure, patient population and referrals at the university.

We know this much, just from public sources: first, Planned Parenthood abortionists supply fetuses to Pitt; second, Pitt uses its access to fetal tissue and organs to get major NIH grant money; third, Planned Parenthood enjoys access to people and resources at Pitt.

Needless to say, a quid pro quo over aborted fetal body parts, funded by taxpayers, would be illegal. If what we know publicly about Pitt is damning, imagine what we do not know. Public officials at every level of government must unearth the full scope of the human trafficking and experimental use of aborted infants, and stop enabling these atrocities.

David Daleiden leads The Center for Medical Progress and is responsible for the multi-year undercover video reporting that exposed the trafficking of aborted fetal body parts at Planned Parenthood and other institutions.

The views expressed in this article are the writer's own.

Continue reading here:
University of Pittsburgh Won't Explain its Planned Parenthood Ties | Opinion - Newsweek

Trial treatment with a mythologically-inspired name saves life of young man diagnosed with multiple myeloma – Neos Kosmos

By Stem Cell Doctors

Nikolas Korfias, originally from Kalymnos, had come with his family to the Northern Territory when he was aged 8. By that stage, he had already learnt about Greek mythology, taught in the early years of the Greek education system. He was aware of Perseus, the legendary founder of Mycenae, who had beheaded the monstrous Medusa, the mythical Gorgon known for turning men to stone. Little did he know at the time that three decades later he would battle his own monster, multiple myeloma while being part of the Perseus Trial, and eventually come out a winner so far.

His battle with multiple myeloma began when he came home fresh from a holiday to Greece to see his grandmother in August 2019 where the young entrepreneur, in charge of a transport company, saw a doctor for an ear infection which he couldnt shrug off. I didnt think too much of it, but doctors said my body was fighting something, though levels seemed fine, Mr Korfias told Neos Kosmos.

Tests continued, and it was on a Tuesday after a long weekend in Sydney when he was told that his MRI scan and other tests confirmed he had multiple myeloma.

Id never heard of it before. I didnt know what it was, Mr Korfias said, remembering going home to do a Google search and being in total shock after what he read of the disease which is common for people aged over 60 and rarely appears in those under 40. He was especially sickened by prognostics when it came to the average life expectancy following diagnosis and the fact that there is no cure.

Well versed on multiple myeloma these days, Mr Korfias explains how this type of cancer forms in a type of white blood cell called a plasma cell where cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. In laymens terms, bones are weakened, leaving a hole in the centre of the bone.

I didnt know how to take it, he said, adding that denial followed shock.

I was fit, I felt healthy, and nobody in my family had ever had multiple myeloma, or cancer.

READ MORE:Greek Australian mother loses cancer battle, but still finds a way to give back to Hellenism

After the initial shock, Mr Korfias was told that, being in the early stages of the disease, he qualified for the Perseus trial where newly-diagnosed patients in Australia, Greece and other countries underwent stem cell replacement therapy. For one year, from September 2019, he focused on regaining his health, but in the process he lost his business and his hair though Im not sure how my business would have fared with COVID-19 anyway, he said.

You need to focus your energy on recovery. It takes a lot of mental focus, Mr Korfias said, pointing to the medication and steroids he was on and regular visits to St Vincents hospital which left him tired and swollen. You are getting injected daily. It is good to keep your mind busy, but I decided I needed to spend time on myself. To fight and get through it. I focused on training and having a positive mindset.

During his hospital visits, he met other patients, mainly elderly men. I didnt see anybody young with multiple myeloma, though obviously younger people had other forms of cancer, he said, adding that not seeing others his age with the disease makes it harder for a young person to relate to the disease.

He took very well to the treatment and recovered very quickly. Initially, 20 per cent of plasma cells were affected, but the figure is at one per cent at the moment. My goal is to bring it down to zero, he said.

His body is etched with tattoos of Spartan warriors, and it was their spirit he wanted to channel when undergoing the Perseus Trial during the COVID-19 pandemic a time of isolation made even harder. Knowing that a positive mindset was critical to his recovery, he focused on the positives.

My life was always go go go and work work work so I began to reevaluate things, he said. Youve just got to have less stress, enjoy life and live well.

READ MORE:20 months since her diagnosis, Maria Kampyli unites to fight cancer

During the battle, he thought long and hard about what he would like to do once the ordeal was over, and how he would be able to take all he had learnt and implement life changes. It was at about this time that his brother, George, had a health scare with an infected intestine, and they began talking about the system, and what kind of support is necessary. The two brothers got together and laid the groundwork for Partner N Care, an NDIS provider which they created.

When in hospital, my university studies and interest in business kicked in and I looked at my own experience and knew that I wanted to provide a different service to help people, Mr Korfias said. We not only help people who have multiple myeloma, but also those who have other forms of disabilities, such as Autism and Down Syndrome.

Since their first client, Mary, the service has grown. Our goal is to provide a relateable service, NDIS from people who have actually experienced disability from within the system, he said.

This is something I feel very passionately about.

As for the rest, life is good and Mr Korfias is ready to proceed to the next chapter hopefully marriage with his fiance who has stuck with him throughout the ordeal.

The rest is here:
Trial treatment with a mythologically-inspired name saves life of young man diagnosed with multiple myeloma - Neos Kosmos

An unusual addition to Californias 2022 ballot – CalMatters

By Stem Cell Doctors

Good morning, California. Its Tuesday, May 25.

When you get your November 2022 ballot, it might feel as though youre seeing double: For the first time in history, a race for the same California seat in the U.S. Senate will likely appear twice.

Thats because lawmakers are rushing to tweak a piece of Californias election law that experts say could violate the U.S. Constitution. The problem became apparent when Kamala Harris resigned from the Senate to become vice president and Gov. Gavin Newsom appointed Alex Padilla to fill the seat through the end of Harris term in January 2023. That apparently put the state in danger of contradicting the U.S. Constitution, which says governors temporary appointees can hold their positions only until the people fill the vacancies by election. And theres an election in November 2022 two months before Harris term ends.

To address the constitutional snag, the state Assembly on Monday passed a bill that calls for an election whenever a Senate seat becomes vacant. It also generally requires that election to be held the same day as a regularly scheduled statewide election, to ensure the greatest participation and to avoid the costs and disruptions of standalone statewide special elections whenever possible, according to the bills author, Menlo Park Democratic Assemblymember Marc Berman.

Therefore, if the state Senate also passes the bill, your November 2022 ballot will contain two elections for the same U.S. Senate seat: One for the remainder of Harris term running from November 2022 to January 2023, and one for the new six-year term beginning January 2023.

But Assemblymember Kevin Kiley, the Rocklin Republican who flagged the constitutional issue for the Legislatures lawyers, told me the bill solves the problem in the most undemocratic way possible and argued Newsom should have called a separate special election for Harris seat much earlier. The latter point was echoed by Christine Pelosi, chair of the California Democratic Party Womens Caucus, in a November San Francisco Chronicle op-ed.

A Message from our Sponsor

The coronavirus bottom line:As of Monday, California had3,674,044 confirmed cases (+0.03% from previous day)and61,762 deaths (+0.01% from previous day), according toaCalMatters tracker.

California has administered 36,364,200 vaccine doses, and 49.2% of eligible Californians are fully vaccinated.

Plus: CalMatters regularly updates this pandemic timeline tracking thestates daily actions. Were alsotracking the states coronavirus hospitalizations by county and lawsuits against COVID-19 restrictions.

A Message from our Sponsor

1. OptumServe misses vaccine mark

California agreed to pay health care company OptumServe up to $221 million to coordinate and operate dozens of vaccination sites but the company has fallen far short of the 100,000 doses it told the state it could deliver daily, accounting for just 1.1% of shots given in California since January, CalMatters Caitlin Antonios reports. At least 12 counties have complained to the state that OptumServe has hampered their ability to get shots into arms and at least three have stopped working with the company altogether. Yet despite concerns dating back to at least February, California continued to give OptumServe an ever-larger role in its vaccine rollout.

Its the latest example of California or its contractors underperforming amid the pandemic. The states $50 million MyTurn site, billed as a one-stop-shop for Californians to book vaccine appointments, only accounts for about 27% of shots given each day. Only 0.001% of Californians who signed up on MyTurn to volunteer at vaccine sites were actually able to book shifts. And PerkinElmer, which received a $1.4 billion contract from the state to process COVID-19 tests, has failed to meet mandated turnaround times or daily processing requirements. Making matters worse, the lab PerkinElmer runs in conjunction with the state was recently found to have significant deficiencies that could put its license in jeopardy.

2. Follow the money

Monday was a big day for money in California. Some highlights:

3. Community colleges consider ethnic studies

The more than 2.1 million students who attend Californias 116 community colleges will likely soon have a new graduation requirement: an ethnic studies class. This week, the community college systems Board of Governors is holding a public hearing on the proposal and is expected to vote on the change in July, EdSource reports. The move comes amid a push to integrate ethnic studies into several levels of Californias education system: Lawmakers are consideringa billto make ethnic studies a high school graduation requirement, which would likely use a model curriculum recently passed by the state Board of Education after four years of controversy and four separate drafts. Newsom last year also signed a bill mandating California State University students take an ethnic studies course. The CSU system is implementing that as a lower-division class, which thousands of students take at community college before transferring to a CSU. As a result, community colleges are scrambling to hire ethnic studies faculty but a funding source remains unclear.

A Message from our Sponsor

CalMatters columnist Dan Walters: Newsom is crowing about giving schools billions of extra dollars, but will he hold them accountable for spending it effectively?

Racism is a public health crisis: My bill would help California identify racial and ethnic disparities while addressing structural racism in state policies and budgets, writes state Sen. Richard Pan, a Sacramento Democrat.

Fix youth mental health crisis: Its stunning to realize how many of Californias children do not receive the mental health support they are entitled to and for which we pay federal taxes, argues Lisa Pritzker of the LSP Family Foundation.

A Message from our Sponsor

Podcast: Israeli-Palestinian conflict hits Californias high schools ethnic studies curriculum. // Los Angeles Times

California driver shortage could make trucking school the most lucrative career change. // Mercury News

California is seeing a COVID-19 baby bust. What is causing it? // Los Angeles Times

California prison doctors fear drug treatment program could create new addicts. // Sacramento Bee

Californias stem cell program found a disease cure, but its being blocked by a biotech firm. // Los Angeles Times

San Francisco touts successes in moving homeless off the streets. But the reality is complicated. // San Francisco Chronicle

San Francisco ranks near the bottom of U.S. metro areas in home value increases. // San Francisco Chronicle

Apple mega deal: iPhone maker agrees to huge Sunnyvale expansion. // Mercury News

PG&E to sell San Francisco headquarters for $800 million, wants half of the money returned to customers. // San Francisco Chronicle

Amanda Gormans private school: Mix of rich, poor, arts and social action. // Washington Post

See you tomorrow.

Tips, insight or feedback? Emailemily@calmatters.org.

Follow me on Twitter:@emily_hoeven

Subscribe to CalMatters newslettershere.

Follow CalMatters onFacebookandTwitter.

CalMatters is now available in Spanish onTwitter,FacebookandRSS.

Read more:
An unusual addition to Californias 2022 ballot - CalMatters

The Stem Cell Manufacturing market is projected to reach USD 18.0 billion by 2026 from USD – GlobeNewswire

By Stell Cell Research

New York, May 26, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Stem Cell Manufacturing Market by Product, End User - Global Forecast to 2026" - https://www.reportlinker.com/p05361410/?utm_source=GNW

By product, the consumables segment accounted for the largest share of the Stem Cell Manufacturing market The Stem Cell Manufacturing market by product is categorized into consumables, instruments, and stem cell lines.The consumables segment dominated the market in 2020.

The large share of this segment can be attributed to the frequent purchase of consumables, rising stem cell research, and increasing demand for stem cell therapies.

Asia Pacific: The fastest-growing region in the Stem Cell Manufacturing market.

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to supportive regulatory framework and increasing public-private initiatives to encourage public awareness about stem cell-based treatments.

North America: the largest share of the Stem Cell Manufacturing market North America accounted for the largest share of the Stem Cell Manufacturing market. Factors such as private funding and grants to support the clinical evaluation of stem cells for various applications are the major factors driving the market growth.

Breakdown of primaries The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows: By Respondent Supply Side- 63%, Demand Side- 37% By Designation Executives- 25%, CXOs, Directors--30%, Managers - 45% By Region North America - 40%, Europe - 25%, APAC 20%, LATAM- 10%, MEA- 5%

The Stem Cell Manufacturing market is dominated by a few globally established players such as Thermo Fisher Scientific (US), Merck Millipore (Germany), Lonza Group AG (Switzerland), Danaher Corporation (US), Sartorius AG (Germany), Bio-Rad Laboratories (US), Becton, Dickinson and Company (US), Stemcell Technologies (Canada), Fujifilm Holdings Corporation (Japan), Miltenyi Biotec (Germany), Terumo BCT Inc. (US), Corning Inc. (US), Bio-Techne Corporation (US), Takara Bio Group (Japan), Eppendorf AG (Germany), Getinge (Sweden), Himedia Laboratories (India), Anterogen (South Korea), Cellgenix GMBH (Germany) and Promocell (Germany).

Research Coverage: The report segments the Stem Cell Manufacturing market-based on region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa), Product [Consumables (Culture Media and other consumables), Instruments (Bioreactors & Incubators, Cell Sorters and other instruments) and Stem Cell Lines (Hematopoietic stem cells, Mesenchymal stem cells, Induced Pluripotent Stem cells, Embryonic stem cells, Neural Stem cells and Multipotent adult progenitor stem cells)], Application [Research (Life science research and Drug discovery and development), Clinical (Allogenic stem cell therapy and Autologous stem cell therapy) and Cell & Tissue Banking Applications], End User (Pharmaceutical & Biotechnology Companies, Academic institutes, Research laboratories & contract research organisations, Hospitals and surgical centres, Cell & tissue banks and Other End Users).

The report also provides a comprehensive review of market drivers, challenges, and opportunities in the Stem Cell Manufacturing market

Key Benefits of Buying the Report: The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments.This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies.

The report also helps stakeholders understand the pulse of the Stem Cell Manufacturing market and provides them information on key market drivers, challenges, and opportunities. Read the full report: https://www.reportlinker.com/p05361410/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read the rest here:
The Stem Cell Manufacturing market is projected to reach USD 18.0 billion by 2026 from USD - GlobeNewswire

Jasper Therapeutics Announces New Clinical Trial with the National Institute of Allergy and Infectious Diseases to Evaluate JSP191 in Chronic…

By Stell Cell Research

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced the initiation of a Phase 1/2 clinical trial to evaluate JSP191, the companys first-in-class anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning regimen prior to allogeneic transplant for chronic granulomatous disease (CGD). Jasper Therapeutics and the National Institute of Allergy and Infectious Diseases (NIAID) have entered into a clinical trial agreement in which NIAID will serve as the Investigational New Drug (IND) sponsor for this study.

CGD is a rare, inherited disease of the immune system that develops in infancy or early childhood and results in severe and sometimes life-threatening infections. Allogeneic hematopoietic stem cell transplant is a proven cure for CGD. However, its use is limited because current conditioning agents used to deplete stem cells in preparation for transplantation are genotoxic and associated with limited efficacy and serious adverse effects, including veno-occlusive disease, long-term infertility and secondary malignancies.

We look forward to collaborating with NIAID on this Phase 1/2 clinical trial, which should provide important information about the potential of JSP191 as a safer and more effective conditioning agent for patients with CGD undergoing hematopoietic stem cell transplant, said Kevin N. Heller, M.D., Executive Vice President, Research and Development, of Jasper Therapeutics. Through this clinical trial agreement with NIAID, as well as others with the National Institutes of Health and academic centers, we are continuing to develop JSP191 for additional pretransplant conditioning regimens beyond severe combined immunodeficiency and acute myeloid leukemia/myelodysplastic syndromes, which have demonstrated safety and efficacy in early-stage clinical trials to date.

About JSP191

JSP191 is a first-in-class humanized monoclonal antibody in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow, creating an empty space for donor or gene-corrected transplanted stem cells to engraft. While hematopoietic cell transplantation can be curative for patients, its use is limited because standard high dose myeloablative conditioning is associated with severe toxicities and standard low dose conditioning has limited efficacy. To date, JSP191 has been evaluated in more than 90 healthy volunteers and patients. It is currently enrolling in two clinical trials for acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS) and severe combined immunodeficiency (SCID) and is scheduled to begin enrollment in three additional studies in 2021 for severe autoimmune disease, sickle cell disease and Fanconi anemia patients undergoing hematopoietic cell transplantation.

About Jasper Therapeutics

Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking programs. JSP191, a first-in-class anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It is designed to enable safer and more effective curative allogeneic and autologous hematopoietic cell transplants and gene therapies. In parallel, Jasper Therapeutics is advancing its preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases than is possible today. For more information, please visit us at jaspertherapeutics.com.

See the original post here:
Jasper Therapeutics Announces New Clinical Trial with the National Institute of Allergy and Infectious Diseases to Evaluate JSP191 in Chronic...

Meso-Brain project explores 3D printed stem cells to treat neurological conditions – 3D Printing Industry

By Stell Cell Research

A stem cell research project headed up by Aston University is developing 3D nanoprinting techniques that they claim could revolutionize neuroscience and the treatment of diseases such as Parkinsons and dementia.

The EU-funded Meso-Brain project aims to generate customizable 3D printed networks of stem-cell-derived neurons to produce a new generation of accurate modeling and testing tools.

The project hopes to address the limitations of current neuronal culturing techniques by combining cutting-edge research within human stem cell biology, nanoscale 3D printing, computational network modeling and light sheet microscopy to discover novel treatment options for the long-term alleviation of brain dysfunction.

Meso-Brain hopes to unlock meaningful and practicable insights into the functioning of the brain, and will eventually allow researchers to accurately model brain networks more realistically than ever before.

Cell 3D printing

Stem cells generally serve as a repair system for the body, and, being unspecialized, are able to develop into a variety of different types of cells. As such, stem cells can develop into specialized cells such as blood, muscle, and brain cells, when required.

Cell 3D printing is an area that is receiving growing interest from researchers and 3D printing firms alike as a means of harnessing these desirable properties, particularly for regenerative medicine and bioprinting applications.

For instance, 3D printer OEM 3D systems announced a breakthrough in its Print to Perfusion bioprinting platform earlier this year, which can now rapidly produce full-size human lung scaffolds that can be perfused with living cells to create tissues. Meanwhile, scientists at the University of Buffalo have developed a new 3D bioprinting method that reduces the time needed to create cell-laden hydrogel structures, potentially bringing 3D printed organs closer to reality.

Elsewhere, researchers from the University of New South Wales have developed a novel technique to 3D print bone-mimicking structures containing living cells with potential uses for bone tissue engineering and disease modeling, and a new bioink created by Lund University is capable of supporting new cell and blood vessel growth once transplanted into new material.

In a similar vein to the Meso-Brain project, 3D bioprinting has previously been deployed by medical tech company Fluicell, R&D firm Cellectricon, and the Karolinska Institutet university to arrange neural brain cells into complex patterns in order to model the progress of neurological diseases.

The Meso-Brain project

The project was first launched by Aston University in 2016 with the goal of using nanoscale 3D printing to replicate the brains neural networks. The project has since received further funding from the EUs Horizon 2020 FET-Open program to accelerate the pace of neuroscience research and pharmaceutical drug discovery.

Coordinated by Aston University, the project is made up of six partners from three countries, including human cell culture specialist Axol Bioscience, digital service provider Kite Innovation, the Institute of Photonic Sciences (ICFO), the University of Barcelona, and LZH Laser Zentrum Hannover E.V.

Meso-Brain combines revolutionary tools for micro-fabrication, neuronal network development and monitoring, and functional analysis to bring to light 3D human neuronal networks with tailored characteristics.

Through Meso-Brain, the consortium is working on developing a new type of neural culture and interacting interface system integrated with conductive polymers, that will facilitate electrical stimulation and recording of individual cells.

In naturally developing circuits in the brain, neurons and connections are first generally configured and then gradually refined over time in response to chemical and electrical activity. To replicate this process in the researchers own 3D printed scaffolds, neurons and astrocytes derived from stem cells are developed at specific cytophilic points through the use of chemical messages and electrical activity to promote and drive functional network development.

After this process, functional connectivity maps are drawn using newly-developed mathematical formulations to verify the function of the 3D printed neural network structure.

The customizable properties of the 3D printed scaffolds enable fluorescence imaging and interrogation with photonic and optical approaches, therefore making it possible to see how the neurons interact with each other in real-time.

Future impacts of Meso-Brain

It is hoped that the research developments within Meso-Brain will allow researchers to accurately and dynamically model brain networks to identify neurons in various states of dysfunction and test their reaction to new medicines and other treatments.

According to the project partners, the development of human 3D neuronal networks that exhibit physiologically relevant and reproducible architecture and activity could be foundational to the scientific community, enabling large-scale scientific investigation of human brain network function.

The projects results also hope to facilitate large-scale pharmaceutical testing on human cells and human disease models with stem cells derived from patients, eventually leading to advances in neural transplantations for central nervous system therapy and repair.

Ultimately, the researchers believe Meso-Brain can aid the understanding and treatment of a range of neurological conditions such as dementia, Parkinsons, and brain trauma.

Subscribe to the3D Printing Industry newsletterfor the latest news in additive manufacturing. You can also stay connected by following us onTwitterand liking us onFacebook.

Looking for a career in additive manufacturing? Visit3D Printing Jobsfor a selection of roles in the industry.

Featured image shows a CT brain scan of a cranium with TBI. Image via Qrons.

View post:
Meso-Brain project explores 3D printed stem cells to treat neurological conditions - 3D Printing Industry

Global Flow Cytometry Market (2020 to 2026) – by Technology, Product and Service, Application, End-user and Geography – ResearchAndMarkets.com -…

By Stell Cell Research

DUBLIN--(BUSINESS WIRE)--The "Flow Cytometry Market Based on Technology, Product and Service, Application, End-User, and Geography - Global Forecast up to 2026" report has been added to ResearchAndMarkets.com's offering.

The Flow Cytometry Market is projected to grow at the rate of 8.7% CAGR by 2026. Flow cytometry is a biophysical, laser-based analytical technology that calculates and analyzes various physical features of cells or particles present in a fluid when passed through a laser beam. Flow cytometry has several benefits over conventional analytical techniques such as ELISA, including its capability to provide accurate results within less time at about similar prices.

The key factors propelling the flow cytometry market include the emergence and commercial application of advanced technologies in flow cytometry and the increase in the adoption of flow cytometry in stem cell research and clinical research. Apart from that, the inadequate purchasing power of end-users in emerging countries and high product costs are the factors to impede the growth of the flow cytometry market.

Companies Mentioned

The cell-based flow cytometry technology leads the overall market to maintain its dominance over the forecast period. Growing demand for early diagnosis and increasing consciousness regarding the advantages of cell-based flow cytometry are the factors contributing to its dominance. Moreover, technology has enormous applications in many research domains. The cell-based flow cytometry technology is mainly used in drug discovery for the physiological significance of the results.

In the market for products & services, the reagents & consumables segment has the most significant market share. This is due to the high penetration along with the benefits such as precise outcomes and user-friendly. Moreover, the introduction of new technologies and their detection capability also boost the demand for the products and services.

As per the application segmentation, the research segment has held a significant share in the market. This segment's major share is attributed to the rising number of research and development activities concerning cancer and other diseases. This technology is mostly used in pharmaceutical research and also has application in various researches.

The commercial organization segment has acquired the maximum share in the market due to the vast application of this technology in various verticals. The emergence of several probes and reagents for particular applications in diagnostics and drug discovery is predicted to generate numerous growth opportunities for the segment by serving the users in research and small peripheral laboratories.

North America has occupied the highest share in the flow cytometry market. This is due to the early adoption of advanced technology, high investments in research and developments, and widespread flow cytometry application in diagnostic activities.

High precision of measurement performance by using flow cytometers and the related valuable outcomes accelerates the global demand for flow cytometers among clinicians, drug developers, and food safety technicians. Moreover, higher sensitivity, easy-to-use analysis, and quick outcomes associated with flow cytometry will also likely drive the flow cytometers' global market growth soon.

Key Topics Covered:

1. Executive Summary

2. Industry Outlook

3. Market Snapshot

4. Market characteristics

4.1. Market Overview

4.2. Market Segmentation

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. DRO - Impact Analysis

5. Technology: Market Size & Analysis

6. PRODUCT & SERVICE: Market Size & Analysis

7. Application: Market Size & Analysis

8. END-USER: Market Size & Analysis

9. Geography: Market Size & Analysis

10. Competitive Landscape

10.1. Competitor Comparison Analysis

10.2. Market Developments

10.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships

10.2.2. Product Launches and execution

11. Vendor Profiles

12. Companies to Watch

13. Analyst Opinion

14. Annexure

For more information about this report visit https://www.researchandmarkets.com/r/qr18f6

Here is the original post:
Global Flow Cytometry Market (2020 to 2026) - by Technology, Product and Service, Application, End-user and Geography - ResearchAndMarkets.com -...

Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Fourth Annual Science Day – Business Wire

By Stell Cell Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new research being highlighted as part of the Companys fourth annual Science Day. Modernas Science Day is designed to provide insight into the continued diverse efforts underway at Moderna to better understand how to use mRNA as medicines and vaccines and underscores the Companys continued commitment to basic science and innovation.

Science Day gives us an opportunity to provide insights into the advancements in our platform science and our further understanding of how to use mRNA as both a vaccine and a medicine. Our investments in basic science continue to result in major steps forward in our platforms capabilities, and these have allowed us to open new therapeutic areas and new scientific directions, said Stephen Hoge, M.D., President of Moderna. Our investments in platform research along with our digital backbone and manufacturing plants have enabled us to create first-in-class mRNA medicines and vaccines. Today, we're excited to highlight our work to identify and address SARS-CoV-2 variants of concern, optimize our proprietary lipid nanoparticle (LNP) technology, and deliver mRNA to hematopoietic stem cells.

Moderna currently has 24 mRNA development programs in its portfolio with 14 having entered clinical studies. The Companys updated pipeline can be found at http://www.modernatx.com/pipeline. Moderna and collaborators have published more than 65 peer-reviewed papers.

At this years Science Day, Moderna will present new platform science and preclinical research, including:

mRNA Delivery to Hematopoietic Stem and Progenitor Cells (HSPC)

Of the nearly 30 trillion cells in the body, approximately 90% are of hematopoietic origin. Hematopoietic lineages originating in the bone marrow are intimately involved in maintaining homeostasis and human health. Nonetheless, there are hundreds of hematologic or immune-related disorders caused or exacerbated by cells of the hematopoietic lineage. In a disease setting, cells of hematopoietic origin interact with host tissues to drive chronic inflammatory and immune disorders. Because some hematopoietic stem and progenitor cells (HSPC) have self-renewal and pluripotent properties, targeting HSPC has the potential to modulate underlying chronic inflammation and immune-related disorders.

Advances in lipid nanoparticle (LNP) technology has allowed for delivery to the bone marrow following systemic LNP administration in vivo. This achievement has enabled Moderna scientists to deliver mRNA directly to bone marrow HSPC in vivo, leading to HSPC transfection and long-term modulation of all hematopoietic lineages. This represents a major milestone in impacting chronic inflammatory and immune related disease.

mRNA Engineering: Optimizing Ribosome Load

The ribosome plays a central role in orchestrating the life of mRNA inside the cell. Understanding how to modulate translation by changing mRNA sequence could enable a powerful lever to control the performance of an mRNA drug. To develop such a lever, the Moderna's scientists strove to characterize mechanistically how differences in translation drive differences in protein expression. In this research, an unexpected relationship emerged where mRNAs with low translation initiation rates conferred the highest and most durable levels of protein expression. By understanding the mechanisms that drive this behavior, the Company is taking mRNA design from a guess-and-check discipline into an engineering discipline. With tools in place, and more under development, Moderna is improving its ability to make an mRNA that generates the right amount of the right protein, for the right amount of time, in the right cell type. As Moderna builds these levers into its mRNA drugs, the Company believes it will be able to target more indications with more precision.

Addressing SARS-CoV-2 Variants of Concern

One part of the Companys strategy to remain ahead of the SARS-CoV-2 virus is to closely monitor and address emerging variants of concern and waning immunity. Moderna is using artificial intelligence (AI) and machine learning to predict escape risk. This involves developing statistical models to understand and predict escape risk, including identifying breakthrough sequences from clinical trials and real-world data, examining spike protein biophysical and pseudovirus neutralization data, studying spike mutations and lineage info, and time tracking.

Science Day Webcast Information

Moderna will host its annual Science Day for analysts and investors at 8:00 a.m. ET on Thursday, May 27. A live webcast will be available under Events and Presentations in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Modernas website for one year following the presentation.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Modernas capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Modernas mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 24 development programs are underway across these therapeutic areas, with 14 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit http://www.modernatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential for delivery of mRNA to hematopoietic stem and progenitor cells (HSPC) in vivo; methods of detecting and interrogating HSPC in vivo; the potential for delivering LNPs to hematopoietic stem cells in vivo; the ability to optimize codons and mRNA structures to increase total protein outputs; the potential for the Company to develop processes for controlling protein expression by modifying ribosomal loads; the Companys ability to engineer LNPs capable of accessing difficult-to-transfect primary cells with efficient endosomal escape and high functional mRNA delivery; the Companys strategy for combatting COVID-19, including processes for monitoring emerging variants and waning immunity; and strategies for modeling viral escape. In some cases, forward-looking statements can be identified by terminology such as will, may, should, could, expects, intends, plans, aims, anticipates, believes, estimates, predicts, potential, continue, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Modernas control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the safety, tolerability and efficacy profile of the Moderna COVID-19 Vaccine observed to date may change adversely in ongoing analyses of trial data or subsequent to commercialization; the Moderna COVID-19 Vaccine may prove less effective against variants of the SARS-CoV-2 virus, or the Company may be unsuccessful in developing future versions of its vaccine against these variants; despite having ongoing interactions with the FDA or other regulatory agencies, the FDA or such other regulatory agencies may not agree with the Companys regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; Moderna may encounter delays in meeting manufacturing or supply timelines or disruptions in its distribution plans for the Moderna COVID-19 Vaccine; whether and when any biologics license applications and/or additional emergency use authorization applications may be filed in various jurisdictions and ultimately approved by regulatory authorities; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading Risk Factors in Modernas most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SECs website at http://www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Modernas current expectations and speak only as of the date hereof.

See more here:
Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Fourth Annual Science Day - Business Wire

TScan Therapeutics Adds to Executive Leadership Team and Board of Directors – BioSpace

By Stell Cell Research

Bill Desmarais, Ph.D., MBA, named Chief Business Officer, bringing more than 20 years of business development and partnering experience

Oncology drug development veteran Gabriela Gruia, M.D., appointed to Board of Directors

Timothy Barberich named Chair of Board of Directors

WALTHAM, Mass.--(BUSINESS WIRE)-- TScan Therapeutics, Inc. (TScan), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointments of Bill Desmarais, Ph.D., MBA, as Chief Business Officer, and Gabriela Gruia, M.D., to its Board of Directors. Dr. Desmarais brings more than 20 years of business development, partnering, and research experience to TScan, including his most recent role as Vice President of Business Development of Momenta Pharmaceuticals, where he spearheaded the Companys partnering strategy that led to Momentas $6.5 billion acquisition by Johnson & Johnson. Dr. Gruia is a seasoned oncology drug development executive with more than 25 years of global regulatory and research experience, including at Novartis as Global Head of Drug Regulatory, Oncology. The Company also named Timothy Barberich, the founder and former Chair and CEO of Sepracor Inc. and member of TScans Board, as Chair of the Board of Directors.

We are thrilled to welcome Bill and Gabriela to the TScan team as we continue to advance our pipeline of TCR-T therapies to the clinic for cancers with significant unmet need, said David Southwell, Chief Executive Officer and President at TScan. Bills proven track record of securing key corporate partnerships and licensing collaborations throughout his 20-year career at leading biopharmaceutical companies will be invaluable to TScan as we look to maximize the full potential of our discovery platform in oncology and in other therapeutic areas, including autoimmune disorders and infectious diseases. Gabriela is an accomplished oncology drug developer that spearheaded the worldwide regulatory approval of 12 novel therapeutics throughout her 16-year career at Novartis. We look forward to working with her on our Board. Additionally, we are pleased to have Tim Barberichs leadership as Chair of TScans Board as we continue to progress our programs.

I look forward to leading TScans efforts to work with strategic partners to further unlock the potential of our target discovery platform across the domains of oncology, autoimmune and infectious disease, said Dr. Desmarais.

TScan has a strong commitment to improving the lives of cancer patients. I am honored to join TScans Board of Directors and believe my oncology drug development and regulatory expertise will be beneficial in helping advance TScans pipeline of TCR-T therapies through the clinic, said Dr. Gruia.

Prior to joining TScan, Dr. Desmarais served as Vice President of Business Development of Momenta Pharmaceuticals. Before Momenta, Dr. Desmarais spent 11 years in roles of increasing responsibility within business development and research and development at Eli Lilly & Co. At Lilly, Dr. Desmarais oversaw regional licensing, promotion and distribution, and co-marketing deals in South Korea, Latin America, Russia, and Japan, assisted in drug repositioning efforts and academic collaborations, and managed the scientific pre-due diligence process for potential partnering opportunities. He received his Ph.D. in Biophysics and Structural Biology from Brandeis University, an MBA from Massachusetts Institute of Technology and a B.S. in Cell and Developmental Biology from Purdue University.

Dr. Gruia most recently served as Chief Development Officer at Ichnos Sciences, where she oversaw regulatory sciences, clinical operations, drug safety, clinical pharmacology, biostatistics and clinical outsourcing. Prior to joining Ichnos, Dr. Gruia spent 16 years at Novartis where she served in several senior roles of increasing responsibility, including Senior Vice President and Global Head of Drug Regulatory Affairs Oncology and Head of Medical Writing and Submissions. At Novartis, Dr. Gruia led the world class oncology regulatory affairs organization of approximately 120 associates and managed all regulatory activities in close partnership with research collaborators, preclinical development, the development organization and senior management. Previously, Dr. Gruia held oncology research and development roles at Pfizer, Pharmacia, Aventis and Rhone Poulenc Rorer. Dr. Gruia received her doctorate in medicine from Bucharest Medical School in Romania and a Masters in Breast Pathology and Mammography from Rene Huguenin/Curie Institute Cancer Center in Paris, France. She received her training in oncology and hematology from Rene Descartes University in Paris, France.

Mr. Barberich is founder and former Chair and CEO of Sepracor Inc., a research-based pharmaceutical company which was acquired by Dainippon Sumitomo Pharma Co., Ltd. in 2009 and is now known as Sunovion Pharmaceuticals. Mr. Barberich served as CEO of Sepracor from 1984 to 2007 and as Chair of the Board from 1990 to 2009. Prior to founding Sepracor, Mr. Barberich spent 10 years as a senior executive at Millipore Corporation. He holds a B.S. in chemistry from Kings College.

About TScan Therapeutics

TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The companys lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005238/en/

Link:
TScan Therapeutics Adds to Executive Leadership Team and Board of Directors - BioSpace

→←